← SynDRA
TAFAMIDIS
SynDRA canonical compound SYN0030040 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | TTR |
|---|
| Mechanism of action | Transthyretin amyloid inhibitor |
|---|
| Indication | familial amyloid polyneuropathy (FAP) |
|---|
| Disease area | neurology/psychiatry |
|---|
All known targets
- TTR
- ABCG2
- SLC22A6
- SLC22A8
Mechanisms of action (all sources)
- Transthyretin stabilizer
- Transthyretin amyloid inhibitor
- TTR STABILISER
- Transthyretin stabiliser
- TTR BINDER
- TTR BINDING AGENT
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ALB
- ADORA1
- OPRD1
- HTR1A
- HTR2A
- HTR2B
- HTR2C
- HTR3A
- KCNH2
- MAOA
- MC3R
- MLNR
- NPY1R
- NR1I2
- NR3C1
- OPRK1
- HRH2
- OPRM1
- PDE3A
- PDE4D
- PGR
- PTGS2
- RBP4
- SCN5A
- SLC29A1
- SLC6A2
- SLC6A3
- SLC6A4
- HRH3
- HRH1
- ADORA2A
- HDAC6
- ADORA3
- ADRA1A
- ADRA2A
- ADRA2B
- ADRA2C
- ADRB1
- ADRB2
- AGTR1
Drug classes
- Anti-Inflammatory Agents
- Glucocorticoids
- Immunosuppressive Agents
ATC classes
- N07X · OTHER NERVOUS SYSTEM DRUGS
Cross-references
Synonyms
- VYNDAMAX
- VYNDAQEL
- Vyndamax
- Vyndaqel
- Fx-1006A
- Fx-1006
- tafamidis meglumine
- vyndaqel
- FX1006A
- vynmac
- FX-1005
- FX-1006
- FX1006
- Tafamidis meglumine
- Fx 1006A
- Fx1006A
- UNII-ZU7CF08A1A
- ZU7CF08A1A
- CHEBI:79345
- Tafamidis meglumine [USAN:INN]
- SCHEMBL14783506
- CHEMBL2105675
- Tafamidis meglumine (JAN/USAN)
- SB16821
- FT-0700926
- D09674
- FX005
- Fx 1006
- UNII-8FG9H9D31J
- CHEBI:78538
- 8FG9H9D31J
- C14H7Cl2NO3
- Tafamidis [USAN:INN]
- tafamidisum
- 4his
- 3MI
- Tafamidis (USAN/INN)
Look up TAFAMIDIS in the interactive SynDRA portal →